{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:43:25Z","timestamp":1764603805043,"version":"3.41.2"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":270,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Merkel cell carcinoma (MCC) is a rare, highly aggressive neuroendocrine skin cancer, which typically affects elderly and immunocompromised and\/or immunosuppressed patients. The checkpoint inhibitor avelumab, a mAb targeting the anti-programmed cell death ligand 1 (anti-PD-L1), has revolutionized the treatment of metastatic MCC, achieving dramatic improvements in disease control and overall survival. However, checkpoint inhibitors are associated with the development of immune-related adverse events, such as exacerbation of pre-existing RA. Although most immune-related adverse events can be managed successfully with CSs, their frequent and\/or long-term use runs the risk of undermining the efficacy of immune checkpoint inhibition.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We report two cases of MCC, in which immunosuppressive therapy for the management of RA was administered.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Immunosuppression for (i) pre-existing and (ii) immune checkpoint inhibitor-exacerbated RA was associated with progression of metastatic MCC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Any decision to initiate immunosuppressive treatment for RA in patients receiving immune checkpoint inhibitor therapy should include careful consideration of the risk of potentially fatal cancer progression and be taken after consultation with the patient\u2019s oncologist and rheumatologist. When the immunosuppressive treatment is required, it should be administered for as short a time as possible and under strict clinical and radiological surveillance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkab037","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T13:34:14Z","timestamp":1632836054000},"source":"Crossref","is-referenced-by-count":3,"title":["The treatment of Merkel cell carcinoma with immune checkpoint inhibitors: implications for patients with rheumatoid arthritis"],"prefix":"10.1093","volume":"5","author":[{"given":"Gina","family":"Klee","sequence":"first","affiliation":[{"name":"Department of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Kisch","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, University of Luebeck"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"K\u00fcmpers","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Schleswig-Holstein, Luebeck"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Perner","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Schleswig-Holstein, Luebeck"},{"name":"Pathology, Research Center Borstel, Leibniz Lung Center, Borstel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Schinke","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Luebeck, Luebeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[{"name":"Department of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewan A","family":"Langan","sequence":"additional","affiliation":[{"name":"Department of Dermatology"},{"name":"Dermatological Science, University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Terheyden","sequence":"additional","affiliation":[{"name":"Department of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"2021100606355874200_rkab037-B1","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/sj.bjc.6605306","article-title":"Chronic lymphocytic leukaemia patients have a high risk of Merkel-cell polyomavirus DNA-positive Merkel-cell carcinoma","volume":"101","author":"Koljonen","year":"2009","journal-title":"Br J Cancer"},{"key":"2021100606355874200_rkab037-B2","doi-asserted-by":"crossref","first-page":"dju382","DOI":"10.1093\/jnci\/dju382","article-title":"Risk of merkel cell carcinoma after solid organ transplantation","volume":"107","author":"Clarke","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2021100606355874200_rkab037-B3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/bjc.2016.391","article-title":"History of chronic inflammatory disorders increases the risk of Merkel cell carcinoma, but does not correlate with Merkel cell polyomavirus infection","volume":"116","author":"Sahi","year":"2017","journal-title":"Br J Cancer"},{"key":"2021100606355874200_rkab037-B4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.bjc.6605733","article-title":"Skin cancers associated with autoimmune conditions among elderly adults","volume":"103","author":"Lanoy","year":"2010","journal-title":"Br J Cancer"},{"key":"2021100606355874200_rkab037-B5","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s00105-019-4465-x","article-title":"Immuncheckpointinhibition beim Merkel-Zell-Karzinom [Immune checkpoint inhibition in Merkel cell carcinoma]","volume":"70","author":"Terheyden","year":"2019","journal-title":"Hautarzt"},{"key":"2021100606355874200_rkab037-B6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/CCO.0000000000000363","article-title":"New developments in the biology and the treatment of metastatic Merkel cell carcinoma","volume":"29","author":"Terheyden","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"2021100606355874200_rkab037-B7","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021100606355874200_rkab037-B8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021100606355874200_rkab037-B9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2016.10.022","article-title":"Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs","volume":"71","author":"Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"key":"2021100606355874200_rkab037-B10","doi-asserted-by":"crossref","first-page":"e000897","DOI":"10.1136\/jitc-2020-000897","article-title":"Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients","volume":"8","author":"Leiter","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2021100606355874200_rkab037-B11","doi-asserted-by":"crossref","first-page":"e000313","DOI":"10.1136\/jitc-2019-000313","article-title":"Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program","volume":"8","author":"Walker","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2021100606355874200_rkab037-B12","article-title":"Risk of toxicity after initiating immune checkpoint inhibitor treatment in patients with rheumatoid arthritis","author":"Efuni","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"2021100606355874200_rkab037-B13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2021100606355874200_rkab037-B14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer\u2014clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021100606355874200_rkab037-B15","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/rheumatology\/kez475","article-title":"A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy","volume":"59","author":"Xie","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2021100606355874200_rkab037-B16","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"2021100606355874200_rkab037-B17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2021100606355874200_rkab037-B18","first-page":"1","article-title":"Therapie eines 85-j\u00e4hrigen MCC-Patienten mit rheumatoider Arthritis Thieme Case Report","author":"Terheyden","year":"2021","journal-title":"PD-L1-Inhibitor Avelumab"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkab037\/40461472\/rkab037.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumap\/article-pdf\/5\/3\/rkab037\/40513065\/rkab037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumap\/article-pdf\/5\/3\/rkab037\/40513065\/rkab037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T09:51:08Z","timestamp":1633773068000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkab037\/6377349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8,31]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkab037","relation":{},"ISSN":["2514-1775"],"issn-type":[{"type":"electronic","value":"2514-1775"}],"subject":[],"published-other":{"date-parts":[[2021]]},"published":{"date-parts":[[2021]]},"article-number":"rkab037"}}